Sharie Haugabook is a senior project manager and drug development team lead of the Therapeutics for Rare and Neglected Diseases (TRND) program in the Therapeutics Development Branch of NCATS’ Division of Preclinical Innovation, where she leads and manages early therapeutic development projects in the TRND portfolio.
Prior to joining NCATS in August 2014, she spent seven and a half years at Merck & Company. She supported and led early drug discovery programs in neuroscience and pharmacology, initially as a senior research biochemist and then as an associate principal scientist.
Haugabook received her Ph.D. in biomedical sciences/pharmacology from the Mayo Clinic College of Medicine at the Mayo Graduate School in Rochester, Minnesota. As a postdoctoral fellow, she earned an M.S. in clinical research as an Institute for Research Minority Training on Mental Health and Aging (IRMMA) Fellow at the Medical University of South Carolina. Haugabook earned her B.S. in chemistry with minors in biology and mathematics from the University of Miami.
Haugabook’s current research interest is early drug development efforts for rare and neglected diseases.